ClinicalTrials.gg
Sign In
RecruitingNCT05307809CYNEPSAUpdated Aug 31, 2026

Cytokine Expression in Psoriasis Patients With and Without Joint Involvement

An interventional study of Blood sample collection and Skin sample collection in Psoriasis and Psoriatic Arthritis, sponsored by Poitiers University Hospital. Recruiting at 1 site in France. Open to participants aged 18 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-31.

Primary conditionArthritis, PsoriaticRegistry: PsoriasisReclassifiedWhy we changed it
Registry
Psoriasis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Arthritis, Psoriatic
Why
  1. The study's listed conditions name Arthritis, Psoriatic, a narrower term within Psoriasis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Poitiers University Hospital · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Started Aug 2022; still recruiting 4 years 2 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years to 100 Years
Sex
All
01

Study summary

The objective of the resarch is to study the cytokine profile of patients with psoriatic arthritis and psoriasis in order to better understand the pathophysiology of the disease and the contribution of cytokines to the presence or absence of joint involvement. This research will compare cytokines levels in sera, in PBMC culture after LPS or CD3/CD28 agonist antibodies, and in skin biopsy.

Read the detailed description

Psoriatic arthritis and Cutaneous Psoriasis are polygenic inflammatory disorders with high burden on the quality of life of patients. Pathophysiology of those disease remain incompletely understood. Recent publications seem to demonstrate an implication of IL-1 family cytokines in the pathogenesis of both diseases. In the literature, results are discordant and focus mainly on cytokines levels in serum of patients. Moreover, few studies compare psoriatic arthritis patients with cutaneous psoriasis patients. We propose here to study cytokines profiles of patients with those conditions in sera, after ex-vivo stimulation of peripheral blood mononuclear cells, and in skin biopsies.

02

Conditions studied

  • Psoriasis
  • Psoriatic Arthritis

Browse trials for

03

In context

Arthritis, Psoriatic Reclassified

600 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

This study's planned enrollment of 40 is below the median of 145 across 336 interventional studies indexed under Arthritis, Psoriatic.

Browse Arthritis, Psoriatic studies →

Lead sponsor

Poitiers University Hospital is the lead sponsor of 314 studies on the registry; 62 are open to participants now.

Browse Poitiers University Hospital studies →

Compared within Arthritis, Psoriatic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Psoriasis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For psoriasis patients :

    • Age over 18 years old
    • Signed
    • 5 year old psoriasis at least
    • At least one skin lesion over 2 cm
    • Without any articular symptoms
    • Without any DMARDs
    • Without anticoagulant treatments or coagulation disease
    • With normal articular and enthesis sonography

  • For psoriatic arthritis patients :

    • Age over 18 years old
    • Signed informed consent
    • Psoriatic arthritis according to CASPAR criteria
    • Without any DMARDs
    • Without anticoagulant treatments or coagulation disease
    • With at least one synovitis at inclusion

  • For controls

    • Age and sex matched with a patient without any rheumatic or dermatologic medical conditions
    • No treatment with corticosteroïds or non-steroïdial anti-inflammatory drugsAge over 18 years old

Exclusion criteria

Exclusion criteria:

▪ For psoriasis patients :

  • Joint damage according to CASPAR criteria
  • Echography activity in favor of chronic inflammatory rheumatism
  • For patients and controls:
  • Without social protection rights
  • People under judiciary protection, of less than 18 years old, pregnant woman, breast feeding women, jailed patients.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Psoriasis

    Other: Blood sample collection · Other: Skin sample collection

  • Experimental
    Psoriatic arthritis

    Other: Blood sample collection · Other: Skin sample collection

  • Active comparator
    Controls

    Other: Blood sample collection

Interventions

  • OtherBlood sample collection

    Blood sample collection

  • OtherSkin sample collection

    Skin sample collection

06

What researchers measure

Primary outcomes

  1. Comparison of cytokine levels in sera, after culture of PBMC stimulated with LPS or CD3/CD28 agonist antibodies between the three groups

    Comparison of cytokine levels in sera, after culture of PBMC stimulated with LPS or CD3/CD28 agonist antibodies between the three groups

    Time frame: At inclusion

Secondary outcomes

  1. Comparison of cytokine levels in skin biopsies between Psoriatic Arthritis and Cutaneous Psoriasis patients

    Comparison of cytokine levels in skin biopsies between Psoriatic Arthritis and Cutaneous Psoriasis patients

    Time frame: At inclusion

  2. Correlation of cytokine levels with rheumatologic disease activity, or dermatologic disease activity

    Correlation of cytokine levels with rheumatologic disease activity, or dermatologic disease activity

    Time frame: At inclusion

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Publication of the results

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Results will be published in a scientific journal

Access criteria: Upon reasonable request to authors after article publication

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2022 (actual). Primary completion is estimated for Feb 2027, 54 months after the start.

Of 67 non-industry interventional studies with no phase under Arthritis, Psoriatic, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 43. This study's planned 54 months is above that.

Counting every sponsor, half of 72 studies reached it within 31 months; a quarter within 13 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2022
First posted
Apr 1, 2022
StartActual
Aug 17, 2022
Primary completionEst.
Feb 17, 2027
CompletionEst.
Feb 18, 2027
Last update
Aug 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05307809
Lead sponsor
Poitiers University Hospital
Responsible party
Sponsor
First posted
Apr 1, 2022
Start date
Aug 17, 2022
Primary completion
Feb 17, 2027 (estimated)
Completion
Feb 18, 2027 (estimated)
Last update
Aug 31, 2026

Study contacts

Guillaume LARID
Contact
rhumatologie@chu-poitiers.fr
+33549444465
Guillaume LARID
principal investigator · Poitiers University Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Arthritis, Psoriatic →

Other studies from this sponsor

Poitiers University Hospital →

Start the discussion